Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia

DISEASE CHARACTERISTICS:

* Relapsed acute myeloid leukemia or acute lymphoid leukemia after allogeneic peripheral blood stem cell transplantation (PBSCT), documented by 1 of the following:

  * Morphologic relapse defined as 1 or more of the following:

    * Peripheral blasts in absence of growth factor therapy
    * Bone marrow blasts greater than 5% of nucleated cells
    * Extramedullary (CNS, testicular, or other sites)
  * Flow cytometric relapse defined as appearance in peripheral blood or bone marrow of cells with abnormal immunophenotype consistent with leukemia recurrence and noted at pretransplant
  * Cytogenetic relapse defined as:

    * Appearance in 1 or more metaphases from bone marrow or peripheral blood cells of nonconstitutional cytogenetic abnormality noted in at least 1 cytogenetic study performed prior to transplant OR
    * New abnormality known to be associated with leukemia
* Allogeneic PBSCT from related (HLA identical and 1 antigen mismatch) OR unrelated (match) donor

  * Must have achieved complete remission after PBSCT
* Current donor must be same as prior donor

  * Age 10 and over

PATIENT CHARACTERISTICS:

Age:

* Not specified

Performance status:

* SWOG 0-2

Life expectancy:

* At least 3 months

Hematopoietic:

* See Disease Characteristics

Hepatic:

* Bilirubin no greater than 2.0 mg/dL

Renal:

* Creatinine no greater than 2.0 mg/dL

Cardiovascular:

* No congestive heart failure requiring diuretics
* No uncontrolled arrhythmia

Pulmonary:

* No pulmonary dysfunction requiring oxygen therapy
* No pneumonia or severe obstruction
* FEV\_1 at least 50% of predicted OR no greater than 50% decline from baseline
* No severe restrictive lung disease (total lung capacity less than 60% or 50% declined from baseline) not due to leukemia

Other:

* No sepsis, aspergillosis, or other active infection

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* See Disease Characteristics

Chemotherapy:

* Not specified

Endocrine therapy:

* Not specified

Radiotherapy:

* Not specified

Surgery:

* Not specified

Other:

* No concurrent cyclosporine or tacrolimus during induction chemotherapy